Ultime notizie per PTC (NASDAQ:PTC) Azioni

PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).

PTC Inc

PT CHANDRA ASRI U/ADR by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

PURETECH HEALTH PLC ORD by PureTech Health PLC

PureTech Health PLC

PetroGas Co

Petrocorp Inc

PTC Therapeutics Inc

PT WILMAR CAHAYA INDNSIA by PT Wilmar Cahaya Indonesia TBK

PARADE TECHS LTD SP/GDR by Parade Technologies Ltd.

Parade Technologies Ltd

Baird analyst Joe Vruwink maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $226 to $228.

News

Price Target

Analyst Ratings

Baird Maintains Outperform on PTC, Raises Price Target to $228

RBC Capital analyst Matthew Hedberg maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $202 to $230.

RBC Capital Maintains Outperform on PTC, Raises Price Target to $230

Piper Sandler analyst Clarke Jeffries maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Neutral and raises the price target from $182 to $202.

Piper Sandler Maintains Neutral on PTC, Raises Price Target to $202

Earnings

Guidance

PTC Sees FY 2024 Revenue $2.505B-$2.605B Vs $2.293B Est

Buybacks

PTC Authorizes $2B Share Repurchase Through 2027, Plans $300M Buyback In Fiscal 2025 As Part Of Strategy To Return 50% Of Free Cash Flow To Shareholders

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.45 by 6.21 percent. The company reported quarterly sales of $626.55 million which beat the analyst consensus estimate of $620.53 million by 0.97 percent. This is a 14.62 percent increase over sales of $546.62 million the same period last year.

Earnings Beats

PTC Q4 2024 Adj EPS $1.54 Beats $1.45 Estimate, Sales $626.55M Beat $620.53M Estimate

WIIM

ACIW

ADBE

ADEA

ADSK

AEYE

AGYS

AISP

AIXI

ALKT

ANSS

APPF

APPN

ARBK

ASAN

BILL

BLKB

BRZE

BTCM

BTCS

BTCT

CCSI

CIFR

CRWD

CVLT

CWAN

CYBR

DATS

DJCO

DOCU

DOMO

EGAN

EVCM

FICO

FTNT

GRYP

GTLB

HTCR

HUBS

IDAI

IDCC

INTA

INTU

IREN

KVYO

LMFA

MANH

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MNDY

MSTR

NCNO

ORCL

PANW

PCOR

PLTR

SDIG

SLNH

SNPS

SOUN

SPNS

SPSC

SSTI

TENB

VRNS

WDAY

XTKG

ZETA

Shares of software companies are trading higher in sympathy with overall market strength after Donald Trump was elected president of the United States.

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect PTC to report an earnings per share (EPS) of $1.45.
PTC bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.02, leading to a 1.11% drop in the share price on the subsequent day.
Here's a look at PTC's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.96</td>
<td>1.23</td>
<td>0.96</td>
<td>1.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.98</td>
<td>1.46</td>
<td>1.11</td>
<td>1.20</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730829714_0.png" alt="eps graph" />
<h3>Performance of PTC Shares</h3>
Shares of PTC were trading at $186.225 as of November 04. Over the last 52-week period, shares are up 26.53%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on PTC</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding PTC.
PTC has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $210.5, the consensus suggests a potential 13.04% upside.
<h3>Peer Ratings Comparison</h3>
The below comparison of the analyst ratings and average 1-year price targets of Zoom Video Comms, Tyler Technologies and Samsara, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Buy trajectory for Zoom Video Comms, with an average 1-year price target of $77.8, indicating a potential 58.22% downside.</li>
<li>As per analysts' assessments, Tyler Technologies is favoring an Outperform trajectory, with an average 1-year price target of $678.91, suggesting a potential 264.56% upside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Samsara, with an average 1-year price target of $44.79, indicating a potential 75.95% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
In the peer analysis summary, key metrics for Zoom Video Comms, Tyler Technologies and Samsara are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTC</td>
<td>Buy</td>
<td>-4.37%</td>
<td>$406.72M</td>
<td>2.32%</td>
</tr>
<tr>
<td>Zoom Video Comms</td>
<td>Buy</td>
<td>2.09%</td>
<td>$877.43M</td>
<td>2.60%</td>
</tr>
<tr>
<td>Tyler Technologies</td>
<td>Outperform</td>
<td>9.84%</td>
<td>$237.46M</td>
<td>2.37%</td>
</tr>
<tr>
<td>Samsara</td>
<td>Neutral</td>
<td>36.92%</td>
<td>$226.84M</td>
<td>-5.25%</td>
</tr>
</tbody>
</table>

Key Takeaway:
PTC ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.
<h3>About PTC</h3>
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).
<h3>Financial Milestones: PTC's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: PTC's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -4.37%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: PTC's net margin excels beyond industry benchmarks, reaching 13.3%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): PTC's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.32%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): PTC's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.12%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: PTC's debt-to-equity ratio stands notably higher than the industry average, reaching 0.66. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/PTC/earnings">To track all earnings releases for PTC visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of PTC's Earnings

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.82% on an annualized basis producing an average annual return of 17.15%. Currently, PTC has a market capitalization of $22.06 billion. 
Buying $1000 In PTC: If an investor had bought $1000 of PTC stock 10 years ago, it would be worth $4,880.12 today based on a price of $183.59 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729800023_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning PTC Stock In The Last 10 Years

In the latest quarter, 6 analysts provided ratings for PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for PTC, revealing an average target of $201.0, a high estimate of $226.00, and a low estimate of $182.00. This upward trend is evident, with the current average reflecting a 2.2% increase from the previous average price target of $196.67.
<img src="https://www.benzinga.com/files/images/story/2024/1729598457_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of PTC by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$226.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$206.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$182.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to PTC. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PTC compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of PTC's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of PTC's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PTC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PTC analyst ratings.</a>
<h2>Unveiling the Story Behind PTC</h2>
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).
<h3>Financial Milestones: PTC's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: PTC's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -4.37%. This indicates a decrease in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: PTC's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): PTC's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.32%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): PTC's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.12%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.66, PTC faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From PTC Analyst Ratings: What You Need To Know

Baird analyst Joe Vruwink maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $216 to $226.

Baird Maintains Outperform on PTC, Raises Price Target to $226

Oppenheimer has initiated coverage on Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>), a clinical-stage biotechnology company focused on developing treatments <a target="_blank" href="https://www.benzinga.com/quote/LRMR" rel="noreferrer noopener">for rare diseases</a>.
The analysts view the company&#8217;s lead program, Nomlabofusp, as a differentiated, disease-modifying therapy that targets the key pathogenic mechanism of frataxin (FXN) deficiency in Friedreich&#8217;s ataxia (FA).
Lower FXN levels predict early onset, disease severity, and faster progression.
Friedreich&#8217;s ataxia is a rare neurodegenerative disease affecting ~20,000 patients globally.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38949290/larimar-therapeutics-friedreichs-ataxia-investigational-drug-differentiated-from-bi" rel="noreferrer noopener">Larimar Therapeutics&#8217; Friedreich&#8217;s Ataxia Investigational Drug Differentiated From Biogen&#8217;s Marketed Drug</a>.
Oppenheimer expects open-label extension (OLE) interim data in the fourth quarter of 2024.
Larimar intends to expand into the pediatric population and pursue accelerated approval with a potential FDA marketing application submission in the second half of 2025 under the FDA&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40215310/larimar-therapeutics-reports-second-quarter-2024-operating-and-financial-results" rel="noreferrer noopener">START Pilot Program</a>.
Oppenheimer has initiated with an Outperform rating and a <a href="https://www.benzinga.com/quote/LRMR/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $26</a>.
The analysts assume a 60% chance of accelerated approval, modeling the U.S. launch in 2027 and the European launch in 2028 for FA, estimating $1.2 billion in global revenues in 2030.
Following early 2023 approval, Skyclarys, developed by Reata and acquired by Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) for $7.3 billion in 2023, has generated ~$278 million <a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33440534/biogen-bolsters-rare-disease-portfolio-agrees-to-buy-reata-pharmaceuticals-with-enterprise-value-" rel="noreferrer noopener">in global sales</a>.
Oppenheimer says that Nomlabofusp stands out from its competitors due to its potential to modify the disease.
Although Reata/Biogen&#8217;s Skyclarys has received approval for patients aged over 16 with FA and PTC Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) vatiquinone is approved for patients over 7, Larimar&#8217;s strategy to include pediatric and adolescent FA patients in its Phase 2 OLE trial enables it to address a larger patient demographic and tackle the progressive aspects of the disease.
Price Action: LRMR stock is up 2.56% at $7.61 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41364884/why-aspen-aerogels-shares-are-seeing-blue-skies-on-wednesday" target="_blank" rel="noreferrer noopener">Why Aspen Aerogels Shares Are Seeing Blue Skies On Wednesday</a>.</li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Initiation

Movers

General

BIIB

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Rosenblatt analyst Blair Abernethy maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Buy and maintains $195 price target.

Rosenblatt Maintains Buy on PTC, Maintains $195 Price Target

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 6.25% on an annualized basis producing an average annual return of 18.13%. Currently, PTC has a market capitalization of $21.42 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 10 years ago, it would be worth $525.56 today based on a price of $178.30 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728489621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In PTC 10 Years Ago Would Be Worth Today

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.76% on an annualized basis producing an average annual return of 17.1%. Currently, PTC has a market capitalization of $21.65 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 10 years ago, it would be worth $479.45 today based on a price of $180.23 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727796662_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today

Collaboration to Drive PTC's Onshape Initiatives Including Discovery Program, Onshape AI Advisor, and CAD and PDM Conversion Tools
BOSTON, Sept. 25, 2024 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262786-1&amp;h=1683162161&amp;u=https%3A%2F%2Fwww.ptc.com%2F&amp;a=PTC">PTC</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) today announced entry into a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to accelerate the growth of its Onshape&#xAE; cloud-native computer-aided design (CAD) and product data management (PDM) solution. This collaboration will focus on advancing Onshape product enhancements, customer adoption programs, and artificial intelligence (AI) initiatives, all of which are aimed at helping product designers and engineers create new, high-quality products faster and more efficiently.

PTC Announces Strategic Collaboration Agreement With AWS To Help Companies Design Products Faster And Easier With Onshape

Management

PTC Board Appointed Neil Barua To Dual Positions Of President And Chief Executive Officer Of Co

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.15% on an annualized basis producing an average annual return of 15.87%. Currently, PTC has a market capitalization of $20.86 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 10 years ago, it would be worth $432.75 today based on a price of $173.62 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725465616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In PTC 10 Years Ago Would Be Worth This Much Today

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.39% on an annualized basis producing an average annual return of 16.21%. Currently, PTC has a market capitalization of $21.16 billion. 
Buying $1000 In PTC: If an investor had bought $1000 of PTC stock 10 years ago, it would be worth $4,500.00 today based on a price of $176.17 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724268622_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In PTC 10 Years Ago Would Be Worth Today

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.79% on an annualized basis producing an average annual return of 16.28%. Currently, PTC has a market capitalization of $20.14 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 10 years ago, it would be worth $449.24 today based on a price of $168.16 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722958219_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PTC Inc. 2024 Q4 - Results - Earnings Call Presentation

PTC Inc. (PTC) Q4 2024 Earnings Call Transcript

Mizuho Securities analyst Siti Panigrahi has maintained their neutral stance on PTC stock, giving a Hold rating on October 31. Siti Panigrahi has g...

PTC's Neutral Outlook: Strong Q4 Results Offset by Cautious FY2025 Guidance and Strategic Transition Challenges

In a report released today, Jason Celino from KeyBanc maintained a Buy rating on PTC (PTC – Research Report). The company's shares closed yesterday...

PTC (PTC) Receives a Buy from KeyBanc

In a report released today, Yun Kim from Loop Capital Markets maintained a Buy rating on PTC (PTC – Research Report), with a price target of $240.0...

PTC (PTC): New Buy Recommendation for This Technology Giant

RBC Capital raised the firm's price target on PTC (PTC) to $230 from $202 and keeps an Outperform rating on the shares. The company delivered a sol...

PTC price target raised to $230 from $202 at RBC Capital

Freshworks, IonQ among tech stocks soaring after earnings, while Dynatrace dips

KeyBanc feels strongly about software stocks under Trump presidency

Stephen Mandel's Lone Pine Capital disclosed in an SEC filing its holdings as of September 30, 2024. The fund's four new buys during the third quar...

Lone Pine buys UnitedHealth, exits Workday in Q3

In a report released yesterday, Siti Panigrahi from Mizuho Securities maintained a Hold rating on PTC (PTC – Research Report). The company's shares...

PTC (PTC) Receives a Hold from Mizuho Securities

AMZN

ARES

ASML

AVDX

AZPN

CDNS

CRSR

EPAM

FRSH

IONQ

MSFT

PAYC

PCTY

TEAM

TRMB

Press Releases

Cellebrite Appoints Tech Veteran Troy K. Richardson to Board of Directors

PTC Will Participate in Upcoming Investor Conferences

PTC Appoints Rob Bernshteyn to Board of Directors

PTC Announces Strategic Collaboration Agreement with AWS to Help Companies Design Products Faster and Easier with Onshape

Vimeo Appoints Enterprise Software Veteran Charlie Ungashick to Drive Innovation as Chief Marketing Officer

Snyk's AI-Native SAST Product Passes $100M in ARR

PTC to Announce Fiscal Q4'24 Results on Wednesday, November 6th, 2024

PTC ANNOUNCES $2 BILLION SHARE REPURCHASE AUTHORIZATION

Fintech

PTC ANNOUNCES FOURTH FISCAL QUARTER AND FULL FISCAL YEAR 2024 RESULTS

CLBT

CLBTW

VMEO

Adobe

Autodesk

Ansys

Applovin Corporation - Class A Common Stock

AppLovin

Aspen Technology

Cadence Design Systems, Inc. - Common Stock

Cadence Design Sys

Salesforce

Datadog

DocuSign

Fair Isaac

Guidewire Software

HubSpot

Intuit

Samsara

Manhattan Associates, Inc. - Common Stock

Manhattan Associates

MicroStrategy Incorporated - Class A Common Stock

MicroStrategy

Nutanix

Palantir Technologies Inc. Class A Common Stock

Palantir Technologies

Comments

PTC

Notizie

Ultime notizie per PTC (NASDAQ:PTC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO